Roth Capital Issues Optimistic Forecast for ZVRA Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Stock analysts at Roth Capital upped their Q1 2025 earnings per share (EPS) estimates for Zevra Therapeutics in a report released on Sunday, February 9th. Roth Capital analyst J. Aschoff now expects that the company will post earnings of ($0.27) per share for the quarter, up from their prior forecast of ($0.30). The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. Roth Capital also issued estimates for Zevra Therapeutics’ Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at $0.01 EPS, Q4 2025 earnings at $0.09 EPS, FY2025 earnings at ($0.17) EPS, FY2026 earnings at $0.82 EPS, FY2027 earnings at $1.53 EPS and FY2028 earnings at $1.97 EPS.

Other equities analysts have also issued research reports about the stock. Cantor Fitzgerald upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a report on Wednesday, January 29th. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Finally, Canaccord Genuity Group dropped their price target on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Zevra Therapeutics presently has an average rating of “Buy” and an average target price of $21.57.

Zevra Therapeutics Stock Performance

NASDAQ ZVRA opened at $7.72 on Wednesday. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The company has a market capitalization of $412.06 million, a PE ratio of -3.92 and a beta of 2.00. The business’s 50-day moving average price is $8.26 and its 200 day moving average price is $8.03. Zevra Therapeutics has a twelve month low of $4.20 and a twelve month high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). The business had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $5.04 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same period in the prior year, the company earned ($0.40) EPS.

Institutional Investors Weigh In On Zevra Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC increased its stake in Zevra Therapeutics by 282,687.5% during the third quarter. FMR LLC now owns 2,313,202 shares of the company’s stock valued at $16,054,000 after purchasing an additional 2,312,384 shares during the last quarter. AIGH Capital Management LLC acquired a new position in shares of Zevra Therapeutics in the 4th quarter valued at about $6,577,000. Stonepine Capital Management LLC bought a new stake in shares of Zevra Therapeutics during the 3rd quarter valued at about $4,858,000. Vestal Point Capital LP acquired a new stake in Zevra Therapeutics during the third quarter worth about $3,644,000. Finally, Propel Bio Management LLC acquired a new stake in Zevra Therapeutics during the third quarter worth about $1,248,000. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.